Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $5.03, reflecting a -1.57% change from the previous day's closing price, underperforming the S&P 500's daily loss of 0.22% [1] - Over the past month, shares of Recursion Pharmaceuticals have increased by 23.28%, while the Medical sector remained flat with a 0% change and the S&P 500 gained 0.45% [1] Upcoming Financial Results - Analysts anticipate Recursion Pharmaceuticals will report earnings of -$0.34 per share, indicating a year-over-year growth of 15% [2] - The consensus estimate for revenue is projected at $15.58 million, representing an 8.02% increase compared to the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at -$1.34 per share and revenue at $74.95 million, reflecting year-over-year changes of +20.71% and +27.38%, respectively [3] Analyst Estimates and Market Sentiment - Recent modifications to analyst estimates for Recursion Pharmaceuticals are crucial as they reflect near-term business trends, with positive revisions indicating optimism about the business outlook [4] - The Zacks Rank system, which evaluates estimate changes, suggests that these alterations are linked to stock price performance in the near future [5] Zacks Rank and Industry Performance - Recursion Pharmaceuticals currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.19% over the past month [6] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries, indicating strong performance potential [7]